RxSight Future Growth
Future criteria checks 2/6
RxSight is forecast to grow earnings and revenue by 31.5% and 21% per annum respectively. EPS is expected to grow by 35.6% per annum. Return on equity is forecast to be -16.2% in 3 years.
Key information
31.5%
Earnings growth rate
35.6%
EPS growth rate
| Medical Equipment earnings growth | 16.1% |
| Revenue growth rate | 21.0% |
| Future return on equity | -16.2% |
| Analyst coverage | Good |
| Last updated | 06 May 2024 |
Recent future growth updates
Recent updates
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05
RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12RxSight: First And Only Customizable Intraocular Lens
Aug 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 210 | -18 | 19 | 14 | 5 |
| 12/31/2025 | 174 | -27 | N/A | 1 | 8 |
| 12/31/2024 | 132 | -36 | -17 | -8 | 8 |
| 12/31/2023 | 89 | -49 | -46 | -42 | N/A |
| 9/30/2023 | 77 | -55 | -51 | -47 | N/A |
| 6/30/2023 | 67 | -59 | -58 | -54 | N/A |
| 3/31/2023 | 58 | -62 | -64 | -62 | N/A |
| 12/31/2022 | 49 | -67 | -61 | -59 | N/A |
| 9/30/2022 | 41 | -67 | -56 | -54 | N/A |
| 6/30/2022 | 35 | -63 | -54 | -52 | N/A |
| 3/31/2022 | 28 | -59 | -51 | -49 | N/A |
| 12/31/2021 | 23 | -49 | -47 | -45 | N/A |
| 9/30/2021 | 19 | -15 | -46 | -44 | N/A |
| 6/30/2021 | 17 | 4 | -40 | -37 | N/A |
| 3/31/2021 | 15 | 17 | -35 | -33 | N/A |
| 12/31/2020 | 15 | 3 | -38 | -35 | N/A |
| 12/31/2019 | 2 | 26 | -45 | -41 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RXST is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RXST is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RXST is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RXST's revenue (21% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: RXST's revenue (21% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RXST is forecast to be unprofitable in 3 years.